董平栓,怯红晓,杜来景,杨旭明,王绍欣,杨喜山,李志娟,朱继红,王红雷,汪砚雨,王可,赵玉伟,闫鹏

• 1:河南科技大学第一附属医院心内科

摘要(Abstract)：

目的观察替罗非班在老年非ST段抬高急性冠状动脉综合征(NSTEACS)介入治疗(PCI)的疗效及对血清可溶性CD40配体(sCD40L)水平的影响。方法将80例经危险度分层为高危的老年NSTEACS患者行介入治疗,随机分为替罗非班组43例,对照组37例,观察住院期间及术后30d内的主要心血管事件(MACE),用酶联免疫吸附法(ELISA)法测定所有入选患者PCI前后血清sCD40L水平。结果与对照组相比,替罗非班组住院期间及术后30d内MACE发生率有所降低(9.5%比18.9%,P>0.05);两组大出血发生率均为0,差异无统计学意义;替罗非班组轻度出血(10/43)较对照组(7/37)有所增加,但差异无统计学意义(P>0.05);替罗非班组治疗后血清sCD40L水平较对照组显著降低(3.17±1.01μg/L比4.05±0.96μg/L,P<0.01)。结论替罗非班可降低MACE发生率,在老年NSTEACS患者PCI中疗效确切,能显著降低sCD40L的水平。

关键词(KeyWords)： 替罗非班;冠状动脉疾病;CD40配体;老年;血管成形术,经腔,经皮冠状动脉

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 董平栓,怯红晓,杜来景,杨旭明,王绍欣,杨喜山,李志娟,朱继红,王红雷,汪砚雨,王可,赵玉伟,闫鹏

参考文献(References)：

• [1]Bovill EG,Terrin ML,Stump DC,et al.for the TIMI investiga-tors.Hemorrhagic events during therapy with recombinan tissue typepla-sminogen activator,heparin and aspirin for acute myro-cardial in-farction.Ann Intern Med,1991,115:256-265.
• [2]The PRISM-PLUS study investigators.Inhibition of the platelet glycoproteinⅡbⅢa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.N Engl J Med,1998,338:1488-1497.
• [3]Egbertson MS,chang CT,Duggan ME,et al.Non-peptide fibrino-gen res-ceptor antagonist optimization of a tyrosine-template as a mimic for Arg-Gy-Asp.Med Chem,1994,37:2537-2551.
• [4]Lef kovittz J,Plow EF,Topol EJ.Platelet glycoprotein IIb/IIIa receptor antagonist trial.Eur Heart J,1999,1(suppl E):182.
• [5]The RESTORE investigators.Effects of platelet glycoproteinⅡb/Ⅲa blockade with irofiban on adverse cardiac events in patents with unstable angina or acute myocardial infarction undergoing coronary angioplasty.Circulation,1997,96:1445-1453.
• [6]叶飞,陈绍良,朱中生,等.老年高危急性冠状动脉综合征患者介入术中应用替罗非班的有效性和安全性.中国介入心脏病学杂志,2007,15:93-95.
• [7]Henn V,Slupsky JR,Grafe M,et al.CD40ligand on activated platelets triggers an inflammatory reaction of endothelial cells.Nature,1998,391:591-594.
• [8]Graf D,Mullar S,Korthauer U,et al.A soluble form of TRAP(CD40ligand)is rapidly released after T cell activation.Eur J Immunol,1995,25:1749-1754.
• [9]Andre P,Nannizzi Alaimo L,Prasad SK,et al.Platelet derived CD40L:the switch hitting player of cardiovascular disease.Cir-culation,2002,106:896-899.